Cognition Therapeutics Inc
NASDAQ:CGTX
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.4612
  • TODAY'S CHANGE (%)
    -0.0504 (-9.8514%)
  • Bid / Lots
    0.4600/ 10
  • Ask / Lots
    0.4700/ 4
  • Open / Previous Close
    0.5000 / 0.5116
  • Day Range
    0.4600
    0.5100
  • 52 Week Range
    0.3400
    2.9500
  • Volume
    336,050

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CGTX
Cognition Therapeutics Inc
18.5M
-0.5x
---
GDTC
CytoMed Therapeutics Ltd
25.1M
-11.0x
---
NRBO
NeuroBo Pharmaceuticals Inc
19.1M
-0.5x
---
FNCH
Finch Therapeutics Group Inc
18.0M
-1.3x
---
GWLL
Goldenwell Biotech Inc
19.8M
-139.9x
---
NNVC
NanoViricides Inc
17.2M
-1.8x
---
As of 2024-11-16

Company Information

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

Contact Information

Headquarters
Suite 261, 2403 Sidney StreetPITTSBURGH, PA, United States 15203
Phone
412-770-1621
Fax
302-697-4597

Executives

Non-Executive Independent Chairman of the Board
Jack Khattar
President, Chief Executive Officer, Director
Lisa Ricciardi
Chief Financial Officer
John Doyle
Chief Medical Officer, Head of R&D
Anthony Caggiano
Independent Director
Aaron Fletcher

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$18.5M
Revenue (TTM)
$0.00
Shares Outstanding
40.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.93
Book Value
$0.76
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.